and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approved for on-demand and perioperative use in adults with VWD and routine prophylactic use in adults with severe Type 3 VWD receiving on-demand therapy.1

VONVENDI is now available for use in a broad range of VWD patients and is the only recombinant von Willebrand Factor (VWF) replacement therapy with approved indications in both adults and children with VWD.1

VWD is the most common bleeding disorder impacting more than 3 million people in the U.S. alone. It occurs equally among men and women. People with VWD have low levels of or dysfunctional von Willebrand factor (VWF), a protein that helps blood clot. This can lead to life-threatening bleeding – either from an injury or after surgery, gastrointestinal bleeding, dental procedures or childbirth – prolonged nosebleeds, heavy or long menstrual bleeding and easy bruising, which can have a significant impact o
=*=*=*=*=*=
当前为第2/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页